SCHEMBL23906148

SCHEMBL23906148

O=C(O)c1ccc(Oc2nc(C3CCOCC3)c(-c3ccc(F)c(F)c3)c3cc4cn[nH]c4cc23)c(F)c1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 1/20 0.37
PRKAB2 O43741 2/20 0.36
PRKAG1 P54619 2/20 0.36
PRKAA2 P54646 2/20 0.36
PRKAA1 Q13131 2/20 0.36
PRKAG3 Q9UGI9 2/20 0.36
PRKAG2 Q9UGJ0 2/20 0.36
PRKAB1 Q9Y478 2/20 0.36
DHODH Q02127 2/20 0.33
MAPK1 P28482 6/20 0.33
MAP4K1 Q92918 2/20 0.32
LRRK2 Q5S007 2/20 0.32
FABP3 P05413 1/20 0.31
FABP4 P15090 1/20 0.31
FABP5 Q01469 1/20 0.31
FAAH O00519 1/20 0.31
ACACB O00763 1/20 0.31
ACACA Q13085 1/20 0.31
PDE9A O76083 1/20 0.30
FYN P06241 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23906155 0.94 PRKAB2 (0.36) FGFR2PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL23884505 0.93 PRKAB2 (0.34) FGFR2PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL30251601 0.93 PRKAB2 (0.34) FGFR2PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL23906181 0.92 PRKAB2 (0.37) FGFR2PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL23906153 0.91 PRKAB2 (0.35) FGFR2PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL23905425 0.89 TOP2A (0.36) FGFR2PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL25474929 0.89 MAPK1 (0.35) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL23906327 0.89 PRKAB2 (0.34) FGFR2PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL23884391 0.88 FGFR2 (0.35) FGFR2PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL25474924 0.88 GCK (0.36) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
WO-2021203025-A1 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINE1, SERPINA3 FGFR2 4885/4885PRKAB2 1493/4885PRKAG1 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.